Instinct Bio Technical Company Holdings Inc. - Warrants (BIOTW)

On our macro desk, the reaction to Instinct Bio's $150 million equity purchase facility was immediate and brutal. Seeing common shares plunge over 70% combined in regular and after-hours trading signals that public market investors are fundamentally exhausted by massive dilution mechanisms coming straight out of the gate after a SPAC combination. For BIOTW holders, this type of structural capital raise severely damages the intrinsic warrant conversion value.

From a risk management standpoint, BIOTW is displaying classic distressed warrant behavior. Trading down near $0.0163 with a 52-week low of $0.0152, the option/warrant structure reflects extreme pessimism. When a target valued at $225 million via a business combination with Relativity Acquisition Corp immediately faces a liquidity crisis of confidence over discretionary stock sales, holding out-of-the-money warrants expiring in July 2031 becomes an exercise in high-beta speculation.

Looking at the order flow and sentiment channels, chatter volume is low to normal, but the psychological narrative is overwhelmingly defensive. Retail traders on forums are treating the SPAC merger with Relativity Acquisition Corp as a cautionary tale of post-de-SPAC liquidations. Without near-term catalysts to reverse the severe post-merger slide, any accumulation in BIOTW looks like a falling knife setup.

In evaluating the clinical and structural thesis, Instinct Bio presents a fascinating dichotomy. On paper, they are positioning themselves as a vertically integrated regenerative medicine and stem-cell skincare platform with a pro forma enterprise value of approximately $288 million. However, the public filing and Form 20-F details reveal that the market is struggling to price the underlying revenue drivers because early disclosures lack deep financial clarity outside of headline equity deals.

As a biotechnology quantitative analyst, I am noting the extreme divergence between the initial pro forma valuation of $225 million (using $10.00 per share Pubco ordinary shares) and the actual trading realities where the equity slid to a fraction of its debut price. The assumption of Relativity warrants into BIOTW means legacy warrant holders are heavily underwater, tracking a common stock that collapsed past $1.33 and lower during after-hours sessions.